Practice Areas

A unit of spirits maker Pernod Ricard has lost its opposition to rival Sazerac's bid to register 'Stagg' as a trade mark for a whiskey brand, with an IP Australia delegate finding the mark was not deceptively similar to Pernod Ricard's 'Royal Stag' mark. 

 DroneShield is facing an ASIC investigation into disclosures and share sales, after its former CEO and two other executives sold all of their shares in the drone defence tech company.

Mayne Pharma cannot access invoices from Cosette’s solicitors at Corrs Chambers Westgarth, with a judge saying he was not hopeful that they would help to resolve a costs fight related to litigation over their collapsed $672 million merger.

At the centre of Tuesday night's budget are tax reforms aimed at investment structures, negative gearing, and the capital gains perk that represent the biggest change to the taxation of Australian savings since 1999.

A judge has permanently stayed a suit against developer Stennson over a Caulfield North residential development after finding the developer would suffer prejudice because the builder on the project was not a party in the case.

Shell’s Australian arm has succeeded in challenging a finding by the ATO that it needed to pay an additional $99 million in capital gains tax after it disposed of its 34.27 per cent holding in Woodside Petroleum.

MinterEllison has denied an administrator’s claims that she was subjected to discrimination and repeated incidents of bullying, saying she frequently raised complaints about "innocuous" interactions with colleagues.

A judge has allowed Adani unit Bravus to bring a $22 million counterclaim against Isaac Regional Council in Queensland, alleging it breached an agreement to upgrade a 96-kilometre road to access the Carmichael mine.

A landlord has won its bid to have lost rent and outgoings assessed as part of damages it is owed after a judge found baked goods producer Allied Pinnacle was required to repaint the outside when its commercial lease at a Western Sydney property ended.

Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.